NCT00879814 - Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Meningitis, Meningococcal

Interventions

BIOLOGICAL

rLP2086 vaccine or control

intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

BIOLOGICAL

rLP2086 vaccine or control

intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

BIOLOGICAL

rLP2086 vaccine or control

intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

BIOLOGICAL

rLP2086 vaccine or control

intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

Trial Locations (1)

Miami Research Associates, Inc., South Miami